Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA approved product is TAVALISSE® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product has been approved by the European Commission for the treatment of chronic immune thrombocytopenia in adult patients who are refractory to other treatments and is marketed in Europe under the name TAVLESSE® (fostamatinib). Fostamatinib is currently being studied in an investigator-sponsored trial conducted by Imperial College London for the treatment of COVID-19 pneumonia.
Rigel's clinical programs include a Phase 3 study of fostamatinib in warm autoimmune hemolytic anemia (AIHA); a completed Phase 1 study of R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) inhibitor program; and an ongoing Phase 1 study of R552, a proprietary molecule from its receptor-interacting protein kinase (RIP) inhibitor program. In addition, Rigel has product candidates in clinical development with partners AstraZeneca, BerGenBio ASA, and Daiichi Sankyo.
Location: United States, California, South San Francisco
Employees: 51-200
Phone: +1 650-624-1100
Founded date: 1996
Investors 2
Date | Name | Website |
07.08.2021 | New Enterp... | nea.com |
- | Frazier Li... | frazierls.... |
Mentions in press and media 35
Date | Title | Description | Source |
10.10.2022 | Rigel Provides Update on Plans for sNDA for wAIHA Program Fo... | --Announces Workforce Reduction-- SOUTH SAN FRANCISCO, Calif., Oct. 10, 2022 /PRNewswire/ -- Rigel ... | einpresswi... |
10.01.2022 | Rigel Pharmaceuticals Provides Business Update | SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL... | marketscre... |
08.01.2022 | Rigel Pharmaceuticals, Inc. Announces Inducement Grants unde... | SOUTH SAN FRANCISCO, Calif., Jan. 7, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)... | marketscre... |
15.11.2021 | Rigel Sharpens Focus on Its Advanced Portfolio Opportunities | SOUTH SAN FRANCISCO, Calif., Nov. 15, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL)... | marketscre... |
02.11.2021 | Rigel Reports Third Quarter 2021 Financial Results and Provi... | Rigel Reports Third Quarter 2021 Financial Results and Provides Business Update - Completed enroll... | marketscre... |
02.11.2021 | Rigel Reports Third Quarter 2021 Financial Results and Provi... | SOUTH SAN FRANCISCO, Calif., Nov. 2, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)... | marketscre... |
26.10.2021 | Rigel Announces Conference Call and Webcast to Report Third ... | SOUTH SAN FRANCISCO, Calif., Oct. 26, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL)... | marketscre... |
08.10.2021 | Rigel Pharmaceuticals, Inc. : Announces Inducement Grants un... | SOUTH SAN FRANCISCO, Calif., Oct. 8, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL)... | marketscre... |
30.09.2021 | Repurposing drugs can speed new treatments for Covid-19 | As the summer of 2021 started to unfold, many Americans thought the pandemic was beginning to fizzle... | statnews.c... |
13.08.2021 | Rigel Pharmaceuticals : Provides Update on COVID-19 Program | SOUTH SAN FRANCISCO, Calif., Aug. 13, 2021 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL... | marketscre... |
Show more